Aileron therapeutics inc (ALRN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-28,904

-29,369

-29,168

-28,853

-31,172

-31,547

0

0

0

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

194

155

129

194

203

218

213

166

153

129

0

0

0

Net amortization of premiums and discounts on investments

227

231

239

254

243

253

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation expense

2,058

2,116

2,228

2,202

3,076

3,280

3,354

3,381

2,319

1,749

0

0

0

Change in deferred rent

-

-

-

-

-

-

-

-

-

11

0

0

0

Gain on sale of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-124

206

673

229

81

117

170

332

520

764

0

0

0

Other assets

0

-

-

-

0

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-129

-103

-162

-147

0

0

0

Accounts payable

230

-277

777

127

-938

130

-52

237

784

-241

0

0

0

Operating lease liabilities

-389

-370

0

0

0

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

1,378

385

-471

-439

216

359

1,062

1,445

1,429

1,216

0

0

0

Net cash used in operating activities

-24,645

-26,474

-26,832

-26,734

-28,498

-27,926

0

0

0

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchases of property and equipment

-

151

2,068

4,341

4,543

4,423

2,559

308

111

142

0

0

0

Proceeds from sale of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investments

-

-

-

-

-

31,194

45,157

83,072

71,339

71,056

0

0

0

Proceeds from sales or maturities of investments

27,466

24,574

32,268

34,450

58,450

60,305

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

271

-2,814

727

-1,606

30,261

24,688

0

0

0

-

-

-

-

Cash flows from financing activities:
Proceeds from exercise of stock options

-

165

179

179

191

42

39

59

52

111

0

0

0

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

471

0

0

0

Net cash provided by financing activities

-

23,964

25,256

26,517

2,664

2,515

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Net decrease in cash, cash equivalents and restricted cash

-575

-5,324

-849

-1,823

4,427

-723

-5,207

3,088

-679

-8,852

0

0

0

Supplemental disclosure of non-cash financing activities:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

41

0

0

0

Issuance costs for redeemable convertible preferred stock included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

0

0

0